← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › PROTEIN KINASE INHIBITORS › Phosphatidylinositol-3-kinase (Pi3K) inhibitors
idelalisib
L01EM01
Forms & Strengths
- Tablets: 100mg, 150mg
- Film-coated tablets
Adult Dosing
- Recommended dose: 150mg orally twice daily
- Dose reduction for adverse reactions: 100mg twice daily
Pediatric Dosing
- Safety and efficacy not established in pediatric patients
- Not recommended for patients under 18 years of age
Indications
- Relapsed chronic lymphocytic leukemia (CLL)
- Relapsed follicular lymphoma
- Relapsed small lymphocytic lymphoma (SLL)
Mechanism of Action
- Selective inhibitor of phosphatidylinositol 3-kinase (PI3K) delta
- Inhibits cell signaling pathways involved in cell growth and survival
Contraindications
- Hypersensitivity to idelalisib or its components
- Severe hepatic impairment
Adverse Reactions
- Diarrhea
- Fatigue
- Nausea
- Neutropenia
- Pneumonitis
- Pyrexia
Drug Interactions
- CYP3A4 inhibitors may increase idelalisib concentrations
- CYP3A4 inducers may decrease idelalisib concentrations
- WARFAIN: increased INR, monitor and adjust warfarin dose
Curated Content: Needs Vetting Before Put to Clinical Use